XTL Biopharma (XTLB) Posts Breakeven Q3 Loss

XTL Biopharma (NASDAQ: XTLB) reported Q3 EPS of ($0.00), versus ($0.00) reported last year.

XTL reported $2.3 million in cash and cash equivalents as of September 30, 2016. Funds will be used to advance the hCDR1 clinical program for the treatment of SLE, to investigate its use in other indications and to identify additional assets for the treatment of other autoimmune diseases.

For earnings history and earnings-related data on XTL Biopharma (XTLB) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Utah Medical Products (UTMD) Reports Q1 EPS of $1.10
• L3Harris Technologies (LHX) Tops Q1 EPS by 15c; raises guidance